Volume 12 Issue 6
Nov.  2021
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2021  >  12(6): 767-772
Ai Liang, Zhang Sheng, Wang Qiang, et al. Progress on biomarkers of EB virus-related posttransplant lymphoproliferative disease[J]. ORGAN TRANSPLANTATION, 2021, 12(6): 767-772. doi: 10.3969/j.issn.1674-7445.2021.06.019
Citation: Ai Liang, Zhang Sheng, Wang Qiang, et al. Progress on biomarkers of EB virus-related posttransplant lymphoproliferative disease[J]. ORGAN TRANSPLANTATION, 2021, 12(6): 767-772. doi: 10.3969/j.issn.1674-7445.2021.06.019
shu

Progress on biomarkers of EB virus-related posttransplant lymphoproliferative disease

doi: 10.3969/j.issn.1674-7445.2021.06.019

  • Department of Transplant Surgery, the Third Xiangya Hospital, Central South University, Changsha 410013, China

More Information
  • Corresponding author: Cheng Ke, Email: Chke1972@163.com
  • Received Date: 2021-08-22
  • Publish Date: 2021-11-15
    Abstract
  • Posttransplant lymphoproliferative disease (PTLD) is a series of heterogeneous lymphoproliferative diseases and a severe complication after solid organ transplantation in children. Over 70% of PTLD is associated with Epstein-Barr virus (EBV). EBV-related B-cell lymphoma is also the main malignant tumor after pediatric organ transplantation. EBV-related PTLD is still a challenge in pediatric solid organ transplantation, which is mainly caused by immune function damage induced by immune suppression after transplantation. However, the specific mechanism remains elusive. In recent years, biomarkers have been developed to guide the diagnosis and individualized treatment of EBV-related PTLD, which possesses excellent application prospect. In this article, research progresses on the incidence of EBV-related PTLD in solid organ transplantation and its biomarkers were reviewed, aiming to explore novel ideas for clinical diagnosis and treatment.

     

    • FullText(HTML)
  • loading
    • References(37)
  • [1]
    HWANG CS, MACCONMARA M, DESAI DM. Pediatric abdominal organ transplantation[J]. Surg Clin North Am, 2019, 99(1): 73-85. DOI: 10.1016/j.suc.2018.09.006.
    [2]
    DESTEFANO CB, MALKOVSKA V, RAFEI H, et al. DA-EPOCH-R for post-transplant lymphoproliferative disorders[J]. Eur J Haematol, 2017, 99(3): 283-285. DOI: 10.1111/ejh.12904.
    [3]
    FRANCIS A, JOHNSON DW, TEIXEIRA-PINTO A, et al. Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study[J]. Nephrol Dial Transplant, 2018, 33(5): 881-889. DOI: 10.1093/ndt/gfx356.
    [4]
    MARTINEZ OM, KRAMS SM, LAPASARAN MG, et al. Prospective analysis of EBV+ PTLD in a multi-center study of pediatric transplant recipients[J]. Transplantation, 2018, 102(Suppl 7): S319.
    [5]
    TERAO T, TSUSHIMA T, FUKUMOTO A, et al. EBV-PTLD in a patient after haploidentical stem-cell transplantation with post-transplant cyclophosphamide[J]. Int J Hematol, 2021, 114(1): 136-140. DOI: 10.1007/s12185-021-03111-z.
    [6]
    明英姿, 彭博, 成柯, 等. 实体器官移植后淋巴组织增生性疾病的研究进展[J]. 器官移植, 2017, 8(2): 89-98. DOI: 10.3969/j.issn.1674-7445.2017.02.002.

    MING YZ, PENG B, CHENG K, et al. Research progress of lymphoproliferative diseases after solid organ transplantation[J]. Organ Transplant, 2017, 8(2): 89-98. DOI: 10.3969/j.issn.1674-7445.2017.02.002.
    [7]
    HOFLAND T, DE WEERDT I, ENDSTRA S, et al. Functional differences between EBV- and CMV-specific CD8+ T cells demonstrate heterogeneity of T cell dysfunction in CLL[J]. Hemasphere, 2020, 4(2): e337. DOI: 10.1097/HS9.0000000000000337.
    [8]
    GAO H, LIU R, WU N, et al. Valproic acid enhances pamidronate-sensitized cytotoxicity of Vδ2+ T cells against EBV-related lymphoproliferative cells[J]. Int Immunopharmacol, 2020, 88: 106890. DOI: 10.1016/j.intimp.2020.106890.
    [9]
    FRASER AR, COOPER R, SMITH LM, et al. Multi-parameter flow cytometric analysis of therapeutic EBV-specific T cells: visual assessment of product development and differentiation using dimensionality reduction with t-SNE[J]. Cytotherapy, 2019, 21(5): S21.
    [10]
    ABUSALAH MAH, GAN SH, AL-HATAMLEH MAI, et al. Recent advances in diagnostic approaches for Epstein-Barr virus[J]. Pathogens, 2020, 9(3): 226. DOI: 10.3390/pathogens9030226.
    [11]
    LAZZAROTTO T, CHIEREGHIN A, PIRALLA A, et al. Kinetics of cytomegalovirus and Epstein-Barr virus DNA in whole blood and plasma of kidney transplant recipients: implications on management strategies[J]. PLoS One, 2020, 15(8): e0238062. DOI: 10.1371/journal.pone.0238062.
    [12]
    SEO E, KIM J, OH SH, et al. Epstein-Barr viral load monitoring for diagnosing post-transplant lymphoproliferative disorder in pediatric liver transplant recipients[J]. Pediatr Transplant, 2020, 24(4): e13666. DOI: 10.1111/petr.13666.
    [13]
    COLOMBINI E, GUZZO I, MOROLLI F, et al. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients[J]. Pediatr Nephrol, 2017, 32(8): 1433-1442. DOI: 10.1007/s00467-017-3627-2.
    [14]
    GREEN M, CHOQUET S. Prevention of Epstein-Barr virus infection and PTLD following SOT[M]//DHARNIDHARKA VR, GREEN M, WEBBER SA, et al. Post-transplant lymphoproliferative disorders. Cham: Springer, 2021: 191-206.
    [15]
    MARTINEZ OM. Biomarkers for PTLD diagnosis and therapies[J]. Pediatr Nephrol, 2020, 35(7): 1173-1181. DOI: 10.1007/s00467-019-04284-w.
    [16]
    MA SD, XU X, PLOWSHAY J, et al. LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis[J]. J Clin Invest, 2015, 125(1): 304-315. DOI: 10.1172/JCI76357.
    [17]
    HATTON O, SMITH MM, ALEXANDER M, et al. Epstein-Barr virus latent membrane protein 1 regulates host B cell microRNA-155 and its target FoxO3a via PI3K p110α activation[J]. Front Microbiol, 2019, 10: 2692. DOI: 10.3389/fmicb.2019.02692.
    [18]
    HASSAN J, DEAN J, DE GASCUN CF, et al. Plasma EBV microRNAs in paediatric renal transplant recipients[J]. J Nephrol, 2018, 31(3): 445-451. DOI: 10.1007/s40620-017-0462-2.
    [19]
    NAVARI M, FULIGNI F, LAGINESTRA MA, et al. Molecular signature of Epstein Barr virus-positive Burkitt lymphoma and post-transplant lymphoproliferative disorder suggest different roles for Epstein Barr virus[J]. Front Microbiol, 2014, 5: 728. DOI: 10.3389/fmicb.2014.00728.
    [20]
    ZIMMERMANN H, OSCHLIES I, FINK S, et al. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry[J]. Transplantation, 2012, 93(5): 543-550. DOI: 10.1097/TP.0b013e318242162d.
    [21]
    SANG AX, HARRIS-ARNOLD A, KAMBHAM N, et al. Epstein-Barr virus-associated lymphoepithelial carcinoma after pediatric liver transplant[J]. Liver Transpl, 2016, 22(6): 849-853. DOI: 10.1002/lt.24457.
    [22]
    DE VLAMINCK I, KHUSH KK, STREHL C, et al. Temporal response of the human virome to immunosuppression and antiviral therapy[J]. Cell, 2013, 155(5): 1178-1187. DOI: 10.1016/j.cell.2013.10.034.
    [23]
    DHARNIDHARKA VR, RUZINOVA MB, CHEN CC, et al. Metagenomic analysis of DNA viruses from posttransplant lymphoproliferative disorders[J]. Cancer Med, 2019, 8(3): 1013-1023. DOI: 10.1002/cam4.1985.
    [24]
    GE Y, ZHOU Z, WANG X, et al. In vitro evaluation of the therapeutic effectiveness of EBV-LMP2 recombinant adenovirus vaccine in nasopharyngeal carcinoma[J]. Biomed Pharmacother, 2020, 121: 109626. DOI: 10.1016/j.biopha.2019.109626.
    [25]
    TAN GW, SIVANESAN VM, ABDUL RAHMAN FI, et al. A novel and non-invasive approach utilising nasal washings for the detection of nasopharyngeal carcinoma[J]. Int J Cancer, 2019, 145(8): 2260-2266. DOI: 10.1002/ijc.32173.
    [26]
    EVENS AM, CHOQUET S, KROLL-DESROSIERS AR, et al. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era[J]. Am J Transplant, 2013, 13(6): 1512-1522. DOI: 10.1111/ajt.12211.
    [27]
    HABIB M, BUISSON M, LUPO J, et al. Lytic EBV infection investigated by detection of soluble Epstein-Barr virus ZEBRA in the serum of patients with PTLD[J]. Sci Rep, 2017, 7(1): 10479. DOI: 10.1038/s41598-017-09798-7.
    [28]
    WANG J, LIU W, ZHANG X, et al. LMP2A induces DNA methylation and expression repression of AQP3 in EBV-associated gastric carcinoma[J]. Virology, 2019, 534: 87-95. DOI: 10.1016/j.virol.2019.06.006.
    [29]
    HOPWOOD PA, BROOKS L, PARRATT R, et al. Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients[J]. Transplantation, 2002, 74(2): 194-202. DOI: 10.1097/00007890-200207270-00009.
    [30]
    HUANG YC, LIN SJ, LIN KM, et al. Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients' survival[J]. Blood, 2016, 128(12): 1578-1589. DOI: 10.1182/blood-2016-02-702530.
    [31]
    SAWADA A, INOUE M. Hematopoietic stem cell transplantation for the treatment of Epstein-Barr virus-associated T- or NK-cell lymphoproliferative diseases and associated disorders[J]. Front Pediatr, 2018, 6: 334. DOI: 10.3389/fped.2018.00334.
    [32]
    TOYODA M, SHIN BH, GE S, et al. Impact of desensitization on antiviral immunity in HLA-sensitized kidney transplant recipients[J]. J Immunol Res, 2017: 5672523. DOI: 10.1155/2017/5672523.
    [33]
    LEE KT, TAN JK, LAM AK, et al. MicroRNAs serving as potential biomarkers and therapeutic targets in nasopharyngeal carcinoma: a critical review[J]. Crit Rev Oncol Hematol, 2016, 103: 1-9. DOI: 10.1016/j.critrevonc.2016.04.006.
    [34]
    MCAULAY KA, HAQUE T, CRAWFORD DH. Tumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease[J]. Br J Cancer, 2009, 101(6): 1019-1027. DOI: 10.1038/sj.bjc.6605278.
    [35]
    GRINDE B. Viruses belonging to anelloviridae or circoviridae as a possible cause of chronic fatigue[J]. J Transl Med, 2020, 18(1): 485. DOI: 10.1186/s12967-020-02666-5.
    [36]
    CAILLARD S, LELONG C, PESSIONE F, et al. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry[J]. Am J Transplant, 2006, 6(11): 2735-2342. DOI: 10.1111/j.1600-6143.2006.01540.x.
    [37]
    AL HAMED R, BAZARBACHI AH, MOHTY M. Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities[J]. Bone Marrow Transplant, 2020, 55(1): 25-39. DOI: 10.1038/s41409-019-0548-7.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (255) PDF downloads(82) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return